The Genesis of Innovation: The RoseWater Energy Story

 

Once upon a time, Joe Piccirilli, CEO, and Mario Bottero, COO of RoseWater Energy saw an opportunity to invest in home energy solutions. There is a need for a reliable and efficient power conditioner, power backup and surge protector for homes.

“Unlike the products we saw out there,” Bottero said, “which was a lot of companies working backward, and saying they need to sell a product, but it can only cost 25 grand, and what can we build for that money, we looked at the problem and said we need to sell a product that’s going to work.”

But the journey to that solution wasn’t short. It took four and a half years before Piccirilli and Bottero had a product worthy of selling and solving the power problems people were having.

“People thought the next generation of energy was going to be solar and a battery, and that was going to cure the ills of the grid,” Piccirilli said. “From the very beginning, our perspective was we weren’t sure that approach was helping anything, and it may be making the grid even worse.” While many said they were crazy, Piccirilli and Bottero stuck to their guns to make their solution a reality.

Piccirilli said RoseWater looked at creating solutions the made sense for all of the players, including both the consumer and the utility company.

“The question is, what does energy look like not just tomorrow, but five years from now, 10 years from now? You can’t just say we’re going to take down the grid. That’s not going to happen,” he said.

And RoseWater’s mission to keep solving energy problems for people will evolve with a constant focus on what they can improve in the future.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More